Download PDF
Fortschr Neurol Psychiatr 2015; 83(12): 665-675
DOI: 10.1055/s-0041-109986
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Parenteral applizierte Antipsychotika bei Agitation und Aggression

Parenteral Antipsychotics in the Treatment of Agitation and Aggression
G. Utzerath
,
D. Reske
,
E. Gouzoulis-Mayfrank
Further Information

Publication History

Publication Date:
29 December 2015 (online)

    Permissions and Reprints

Zusammenfassung

In dieser Übersichtsarbeit wird die wissenschaftliche Datenlage zu den Wirkstoffen Benperidol intravenös, Aripiprazol intramuskulär, Ziprasidon intramuskulär, Haloperidol intramuskulär sowie Loxapin inhalativ bezüglich ihrer Wirksamkeit und Verträglichkeit sowie pharmakodynamischen und pharmakokinetischen Eigenschaften präsentiert. Zudem wird der Einsatz bei Zuständen von Anspannung, Erregung und Aggression im Hinblick auf mögliche Vor- und Nachteile vergleichend diskutiert.

Abstract

This overview presents the current scientific data on intramuscular administration of benperidole, aripiprazole, ziprasidone, and haloperidole and on inhaled loxapine with regard to their efficacy and tolerability as well as their pharmacodynamic and pharmacokinetic properties. In addition, the possible advantages and disadvantages of the different substances are compared when administered to patients who show tension, agitation and aggression.

Schlüsselwörter

Agitation - Aggression - parenterale atypische Antipsychotika - parenterale typische Antipsychotika - intramuskulär - intravenös

Key words

agitation - aggression - parenteral atypical antipsychotics - parenteral typical antipsychotics - intramuscular - intravenous
 

  • Literatur

  • 1 TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ 2003; 327: 708-713
    CrossrefPubMedGoogle Scholar
  • 2 McAllister-Williams RH, Ferrier IN. Rapid tranquillisation: time for areappraisal of options for parenteral therapy. Br J Psychiatry 2002; 180: 485-489
    CrossrefPubMedGoogle Scholar
  • 3 Huf G, da Silva Freire Coutinho E et al. Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro-Brazil: a prevalence study. BMC Psychiatry 2002; 2: 4
    CrossrefPubMedGoogle Scholar
  • 4 Fachinformation Aripiprazol intramuskulär (7,5 mg/ml Injektionslösung). Stand 04.2015
    PubMedGoogle Scholar
  • 5 Leggio GM, Salomone S, Bucolo C et al. Dopamine D(3) receptor as a new pharmacological target for the treatment of depression. Eur J Pharmacol 2013; 719: 25-33
    CrossrefPubMedGoogle Scholar
  • 6 Lee BJ, Lee SJ, Kim MK et al. Effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with risperidone. Clin Psychopharmacol Neurosci 2013; 11: 60-66
    CrossrefPubMedGoogle Scholar
  • 7 Food and Drug Administration. Im Internet: www.fda.gov ; Stand 2015
    PubMedGoogle Scholar
  • 8 Davies MA, Sheffler DJ, Roth BL. Aripiprazol: A novel atypical anti-psychotic drug with a uniquely robust pharmacology. CNS Drug Rev 2004; 10: 317-336
    PubMedGoogle Scholar
  • 9 Naber D, Lambert M. Aripiprazole: a new atypikal antipsychotic with a different pharmacological mechanism. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 1213-1219
    CrossrefPubMedGoogle Scholar
  • 10 Boulton DW, Kollia G, Mallikaarjun S et al. Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia. Clin Pharmacokinet 2008; 47: 475-485
    CrossrefPubMedGoogle Scholar
  • 11 Volavka J, Czobor P, Citome L et al. J Clin Psychiatry. 2005; 66: 1362-1366
    PubMedGoogle Scholar
  • 12 Zimbroff DL, Marcus RN, Manos G et al. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol 2007; 27: 171-176
    CrossrefPubMedGoogle Scholar
  • 13 Tran-Johnson TK, Sack DA, Marcus RN et al. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2007; 68: 111-119
    CrossrefPubMedGoogle Scholar
  • 14 Andrezina R, Josiassen RC, Marcus RN et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology 2006; 188: 281-292
    CrossrefPubMedGoogle Scholar
  • 15 AWMF. Leitlinie Schizophrenie. 2007
    PubMedGoogle Scholar
  • 16 Daniel DG, Currier GW, Zimbroff DL et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. J Psychiatr Pract 2007; 13: 170-177
    CrossrefPubMedGoogle Scholar
  • 17 Fachinformation Benperidol. Stand 04/2013
    PubMedGoogle Scholar
  • 18 Seiler W, Wetzel H, Hillert A et al. Pharmacokinetics and bioavailability of benperidol in schizophrenic patients after intravenous and two different kinds of oral application. Psychopharmacology 1994; 116: 457-463
    CrossrefPubMedGoogle Scholar
  • 19 Garbow L. Comparative studies of Halothane anesthesia and neuroleptic analgesia in thoracic surgery. Anaesthesist 1964; 13: 220-225
    PubMedGoogle Scholar
  • 20 Collard J. Benperidol and placebo: a double blind study in neuroses during ambulatory treatment. Acta Neurol Belg 1964; 64: 353-355
    PubMedGoogle Scholar
  • 21 Fachinformation Haloperidol. Stand 09.2013
    PubMedGoogle Scholar
  • 22 Meyer-Massetti C, Cheng CM, Sharpe BA et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?. J Hosp Med 2010; 5: E8-E16
    PubMedGoogle Scholar
  • 23 Granger B, Albu S. The haloperidol story. Ann Clin Psychiatry 2005; 17: 137-140
    CrossrefPubMedGoogle Scholar
  • 24 Dervaux A, Laqueille X. Tobacco and schizophrenia: therapeutic aspects. Encephale 2007; 33: 629-632
    CrossrefPubMedGoogle Scholar
  • 25 Calver L, Drinkwater V, Gupta R et al. Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomised controlled trial. BMC Psychiatry 2014; 13: 225
    PubMedGoogle Scholar
  • 26 Suzuki H, Gen K, Takahashi Y. A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia. Hum Psychopharmacol 2014; 29: 83-88
    CrossrefPubMedGoogle Scholar
  • 27 Bosanac P, Hollander Y, Castle D. The comparative efficacy of intramuscular antipsychotics for the management of acute agitation. Australas Psychiatry 2013; 21: 554-562
    CrossrefPubMedGoogle Scholar
  • 28 Powney MJ, Adams CE, Jones H. Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). Cochrane Database Syst Rev 2012; 11
    PubMedGoogle Scholar
  • 29 Satterthwaite TD, Wolf DH, Rosenheck RA et al. A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. J Clin Psychiatry 2008; 69: 1869-1879
    CrossrefPubMedGoogle Scholar
  • 30 EMA assessment report. 2012 Im Internet: http://www.ema.europa.eu ; Stand: 04.2015
    PubMedGoogle Scholar
  • 31 Glazer WM. Does loxapine have “atypical” properties? Clinical evidence. J Clin Psychiatry 1999; 60: 42-46
    PubMedGoogle Scholar
  • 32 Fachinformation Loxapin. Stand: 10.2014
    PubMedGoogle Scholar
  • 33 Heel RC et al. Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent. Drugs 1978; 15: 198-217
    CrossrefPubMedGoogle Scholar
  • 34 Tuason VB. A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients. J Clin Psychiatry 1986; 47: 126-129
    PubMedGoogle Scholar
  • 35 Chakrabarti A et al. Loxapine for schizophrena. Cochrane Database Syst Rev 2007; 4: CD001943
    PubMedGoogle Scholar
  • 36 Lesem MD, Tran-Johnson TK, Riesenberg RA et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry 2011; 198: 51-58
    CrossrefPubMedGoogle Scholar
  • 37 Allen MH, Feifel D, Lesem MD et al. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011; 72: 1313-1321
    CrossrefPubMedGoogle Scholar
  • 38 Kwentus J, Riesenberg RA, Marandi M et al. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord 2012; 14: 31-40
    CrossrefPubMedGoogle Scholar
  • 39 Dolovich MB, Macintyre NR, Anderson PJ et al. Consensus statement: aerosols and delivery devices. J Aerosol Med 2000; 13: 291-300
    CrossrefPubMedGoogle Scholar
  • 40 Casas M. Smoking in affective psychosis: review about nicotine use in bipolar and schizoaffective disorders. Adicciones 2011; 23: 65-75
    PubMedGoogle Scholar
  • 41 Goff DC, Henderson DC, Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 1992; 149: 1189-1194
    CrossrefPubMedGoogle Scholar
  • 42 Fachinformation Ziprasidon. Stand: 01.2014
    PubMedGoogle Scholar
  • 43 Citrome L. Using oral ziprasidone effectively: the food effect and dose-response. Adv Ther 2009; 26: 739-748
    CrossrefPubMedGoogle Scholar
  • 44 Jangro WC, Preval H, Southard R et al. Conventional intramuscular sedatives versus ziprasidone for severe agitation in adolescents: case-control study. Child Adolesc Psychiatry Ment Health 2009; 3: 9-14
    CrossrefPubMedGoogle Scholar
  • 45 Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group. J Clin Psychiatry 2000; 61: 933-841
    CrossrefPubMedGoogle Scholar
  • 46 Brook S, Walden J, Benattia I et al. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology (Berl) 2005; 178: 514-523
    CrossrefPubMedGoogle Scholar
  • 47 Miceli JJ, Tensfeldt TG, Shiovitz T et al. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder. Clin Ther 2010; 32: 472-491
    CrossrefPubMedGoogle Scholar
  • 48 Mautone A, Scarone S. Transition from ziprasidone IM to oral formulation in agitated paents with acute exacerbation of schizophrenia: an open trial. Pharmacopsychiatry 2011; 44: 173-178
    Article in Thieme ConnectPubMedGoogle Scholar
  • 49 Daniel DG, Potkin SG, Reeves KR et al. Intramuscular (IM) ziprasidone 20mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology 2001; 155: 128-134
    CrossrefPubMedGoogle Scholar
  • 50 Leucht S. Benperidol for schizophrenia. Cochrane Database Syst Rev 2005; 2
    PubMedGoogle Scholar
  • 51 Komossa K, Rummel-Kluge C, Hunger H et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009; DOI: 10.1002/14651858.
    PubMedGoogle Scholar
  • 52 Benkert O. Wechsel des Antipsychotikums. In: Benkert O, Hippert H, Hrsg Kompendium der Psychiatrischen Pharmakotherapie. Heidelberg: Springer Medizin; 2014: 347-349
    Google Scholar
  • 53 Khanna P, Suo T, Komossa K et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2014; 1 DOI: 10.1002/14651858.CD006569.pub5.
    PubMedGoogle Scholar
  • 54 Rote Liste. Im Internet: www.online.rote-liste.de ; Stand: 06.2015
    PubMedGoogle Scholar